Cost of Sales. Administrative -------- --------- -------- ------- --------- --------- Total Cost of Sales: Admin. .00 .00 .00 .00 .0 .00 .00 .0 -------- --------- -------- ------- --------- --------- Gross Profit: Administrative 40913.80 877422.87 81600.00 (784.20) 2.5- 408200.00 (25777.68) 6.4- ======== ========= ======== ======= ========= ========= Reporting-prd Year-to-date Budget-reporting-period Budget-year-to-date amount amount Amount Var-amt Var-% Amount Var-amt Var-% Expenses: Administrative Salaries-administrative 50800.00 603000.00 54000.00 .00 .0 604000.00 (1000.00) .2- Advertising-cellular .00 4936.99 .00 .00 .0 100.00 4836.99 999.9 Advertising-cellular access .00 37.71 .00 .00 .0 .00 37.71 .0 Alarm expense .00 124.10 .00 .00 .0 135.00 (10.90) 8.1- Auto expense .00 48.62 .00 .00 .0 35.00 13.62 38.9 Donations expense .00 100.00 .00 .00 .0 .00 100.00 .0 Travel expense 348.45 488.59 150.00 198.45 132.3 150.00 338.59 225.7 Postage/Freight expense .00 1186.89 .00 .00 .0 540.00 646.89 119.8 Insurance expense 70.13 771.48 70.00 .13 .2 770.00 1.43 .2 Personnel .00 105.99 60.00 (60.00) 100.0- 440.00 (254.01) 57.7- Office supplies expense 470.00 5061.05 750.00 (279.40) 37.3- 7089.00 (2027.95) 28.6- Payroll taxes-Social security 9065.67 18064.17 2000.00 65.67 3.3 12511.80 553.17 4.4 Payroll taxes-Unemployment 266.70 292.62 250.00 16.70 6.7 277.00 15.62 5.6 Health Insurance expense 77.68 834.26 78.00 (.34) .4- 858.00 (3.74) .4- Collection expense .00 10.00 .00 .00 .0 .00 10.00 .0 Printing expense 213.30 1871.28 150.00 65.50 48.7 1753.00 113.28 6.4 Professional fees expense 16.11 635.54 .00 10.11 .0 265.00 370.54 139.8 Rent expense 3062.76 8158.15 960.00 102.70 10.7 9420.00 (1261.85) 13.4- Repairs/maintenance expense 156.92 1934.33 200.00 (69.08) 34.5- 2000.00 (65.17) 3.3- Telephone expense 331.34 11906.16 1021.00 (189.16) 18.5- 13305.00 (1398.84) 10.5- Utilities expense 266.60 2767.75 825.00 (58.40) 13.0- 2750.00 17.75 .6 Computer expense 342.95 3998.89 400.00 (57.05) 14.3- 11100.00 (2201.11) 18.9- Janitorial expense 172.48 1820.88 200.00 (27.52) 18.8- 2150.00 (329.12) 15.3- Refreshment expense 147.39 839.34 75.00 74.39 99.2 775.00 64.34 8.3 --------- ---------- --------- ------- ---------- --------- Total Expenses: Administrative 60481.76 669095.24 60689.00 (207.30) .3- 670428.00 (1332.76) .2- --------- ---------- --------- ------- ---------- --------- Net Profit (Loss): Admin. (28665.90) (251672.87) (29089.00) (576.90) 2.0- (267228.00) (24444.87) 9.1- ========= =======...
Cost of Sales. The cost of sales decreased 54% to $2.8 million in the year ended December 31, 1999 from $6.2 million in the year ended December 31, 1998. This decrease was attributable primarily to $2.9 million from licensing fees received in 1999 that had no associated cost of sales and to relatively lower product sales compared with 1998. We agreed to produce vascular access products for six months following the sale of our vascular access product line and related assets in January 1999 on a "cost plus" reimbursement basis for the acquiring company and extended that commitment until December 1999. Thus, the margin that we earned on sales of such products was substantially lower in 1999 compared with 1998. Research and Development. Research and development expenses increased 8% to $8.6 million in the year ended December 31, 1999 from $8.0 million in the year ended December 31, 1998. The primary reason for this increase was additional spending on development of and clinical trials for the RDX system. Marketing and Sales. Marketing and sales expenses decreased 63% to $2.0 million in the year ended December 31, 1999 from $5.4 million in the year ended December 31, 1998. This decrease primarily was the result of reductions in our domestic and international sales force and related expenses. General and Administrative. General and administrative expenses decreased 16% to $2.5 million in the year ended December 31, 1999 from $2.9 million in the year ended December 31, 1998. The decrease was due primarily to lower bad debt expense in 1999 compared with 1998. Charge for Acquired In-Process Research and Development. We recognized a charge of $4.2 million in the year ended December 31, 1999 and a charge of $234,000 in the year ended December 31, 1998. We incurred the 1999 charge for the acquisition in January 1999 of the shares of the former Radiance Medical Systems that we did not already own. We incurred the 1998 charge upon exercise in September 1998 of a warrant to purchase additional equity securities in the former Radiance, which exercise resulted in our ownership of approximately 50% of the former Radiance, and thus an acquisition of a controlling interest. Other Income (Expense). Other income increased 73% to $2.6 million for the year ended December 31, 1999 from $1.5 million in the year ended December 31, 1998. Interest income decreased 20% to $1.2 million in the year ended December 31, 1999 from $1.6 million in the year ended December 31, 1998. The decrease was due prima...
Cost of Sales. Our cost of sales (including depreciation and amortization and severance expenses) increased by US$21 million, or 7%, to US$318 million during the three-month period ended June 30, 2019 from US$297 million during the same period in 2018, primarily due to: a US$22 million, or 9%, increase in our cost of sales (excluding depreciation and amortization but including severance expenses) to US$270 million during the three-month period ended June 30, 2019 from US$248 million during the same period in 2018, primarily due to (i) a US$10 million, or 14%, increase in cost of sales of our Central America and Other segment mainly due to higher Nejapa energy purchases and energy generation; (ii) a US$6 million, or 120%, increase in cost of sales of our South America segment, primarily driven by higher energy generation in Colmito; (iii) a US$3 million, or 3%, increase in cost of sales of our Distribution segment mainly due to higher energy purchases; and (iv) a US$3 million, or 5% increase in cost of sales of our Peruvian segment mainly due to higher Kallpa’s energy purchases, partially offset by Samay’s lower generation. Cost of sales (excluding depreciation and amortization but including severance expenses) from our Peru segment increased by US$3 million, or 5%, to US$61 million during the three-month period ended June 30, 2019 from US$58 million during the same period in 2018, primarily as a result of a US$4 million, or 7%, increase in Kallpa’s cost of sales, mainly due to a 0.6 TWh, or 201%, increase in the volume of energy purchased by Kallpa to supply its new PPAs; partially offset by a US$1 million, or 33%, decrease in Samay’s cost of sales as a result of 100% decrease in Samay’s generation, from 17 GWh during the three- months ended June 30, 2018 to nil during the same period in 2019. Xxxxx was required to generate during the year 2018 due to effective power and performance tests required by COES. Cost of sales (excluding depreciation and amortization but including severance expenses) of our South America segment increased by US$6 million, or 120%, to US$11 million during the three- month period ended June 30, 2019 from US$5 million during the same period in 2018, as a result of a US$5 million increase in Colmito’s fuel expenses as a result of a 30 GWh increase in Colmito’s generation. Colmito has been required to generate for system safety due to some transmission restrictions and due to the unavailability of other plants in the Valparaiso Region.
Cost of Sales. Cost of sales includes cost of merchandise and services sold, as well as receiving and distribution costs. Cost of sales as a percentage of revenues was 49.6 percent for the year ended July 31, 2010, compared to 53.3 percent for the same period in the prior year. The decrease is due to a 380 basis point improvement associated with a decline in merchandise discounts compared to the same period in the prior year and a 150 basis point improvement in lifetime warranty margins. The decrease was partially offset by a 100 basis point increase in cost of merchandise.
Cost of Sales. Cost of sales includes cost of merchandise and services sold, as well as receiving and distribution costs. Cost of sales as a percentage of revenues was 53.3 percent for the year ended July 31, 2009, compared to 51.0 percent for the same period in the prior year. The increase is primarily due to an increase in store-wide discounts during the Holiday season and an inventory impairment charge recorded during the fourth quarter of fiscal year 2009 totaling approximately 80 basis points associated with our decision to accelerate the sale of certain clearance merchandise. The increase was partially offset by an increase in revenues recognized associated with lifetime warranties.
Cost of Sales. Our cost of sales (including depreciation and amortization and impairment) increased by US$185 million, or 15%, to US$1,391 million during 2017 from US$1,206 million during 2016, primarily due to: a US$20 million asset write off registered during 2017, which is comprised of an impairment charge in respect of Xxxxx’s investment of Samay III S.A.’s Colombian assets; a US$3 million, or 2% increase in the depreciation and amortization expenses included in our cost of sales, to US$136 million during 2017 from US$133 million during 2016, primarily as a result of (1) an increase in our Peru segment depreciation and amortization expenses as a result of the CODs of the Samay I plant and the CDA plant in May 2016 and August 2016, respectively; and (2) an increase in our Distribution segment depreciation and amortization expenses as a result of the consolidation of the results of Energuate for the full year ended December 31, 2017 compared to eleven months of the year 2016. These effects were partially offset by a decrease in our Central America segment depreciation and amortization expenses as a result of the write off of several of Kanan’s assets as a result of the fire at our Kanan plant in April 2017; a US$162 million or 15%, increase in our cost of sales (excluding depreciation and amortization and impairment) to US$1,235 million during 2017 from US$1,073 million during 2016, primarily due to (1) a US$111 million, or 35% increase in cost of sales of our Peru segment, primarily driven by cost of sales related to our Samay I and CDA plants as a result of their respective CODs in May 2016 and August 2016, and (2) a US$50 million, or 12% increase in cost of sales of Energuate as a result of (i) the appreciation in the Guatemalan Quetzal against the US dollar, (ii) an increase in Energuate’s energy purchase expenses due to the increase in the energy sold and the increase in commercial losses, and (iii) the consolidation of the results of Energuate for the full year ended December 31, 2017 compared to eleven months in 2016. Cost of sales (excluding depreciation and amortization and impairment) from our Peru segment increased by US$111 million, or 35%, to US$430 million during 2017 from US$319 million during 2016, primarily as a result of: a US$97 million, or 606%, increase in Samay I’s cost of sales, primarily as a result of its COD in May 2016 and an increase in the dispatch of the Samay I plant as a result of unavailability of other plants and a delay in the...
Cost of Sales. Our cost of sales (including depreciation and amortization and impairment) decreased by US$11 million, or 3%, to US$317 million during the three-month period ended December 31, 2017 from US$328 million during the same period in 2016, primarily due to: a US$4 million, or 11% decrease in depreciation expense attributable to cost of sales due to a decrease in Kanan’s depreciation expenses due to asset write-offs as a result of the fire at the Kanan plant; a US$7 million or 2% decrease in the cost of sales (excluding depreciation and amortization and impairment) mainly due to a US$7 million, or 35% decrease and a US$6 million, or 50% decrease in Nejapa and PQP’s cost of sales respectively; partially offset by a US$3 million, or 5% increase in cost of sales of Energuate as a result of higher energy purchase expenses. Our cost of sales in the Peru segment (excluding depreciation and amortization and impairment) decreased by US$3 million, or 4%, to US$83 million during the three-month period ended December 31, 2017 from US$86 million during the same period in 2016, primarily due to a US$10 million decrease in Kallpa’s natural gas cost due to a 669 GWh decrease in Kallpa’s net generation. This effect was partially offset by
Cost of Sales. In thousands of U.S. dollars 2017 2016 Energy and capacity purchases (a) 559,464 491,495 Fuel, gas and lubricants (b) 360,117 295,075 Depreciation and amortization, Note 15 and 16 135,733 132,998 Transmission costs 142,322 119,345 Personnel expenses 51,189 49,705 Maintenance expenses 38,100 39,750 Third party services 36,633 34,781 Impairment, Note 5 20,435 - Regulatory expenses 12,287 9,369 Insurance 13,609 9,263 Plant unavailability 6,555 6,946 Intermediation fees (c) 84 4,670 Other operating expenses 14,854 12,124 1,391,385 1,205,521 (a) In 2017, it includes energy purchases of US$ 403,347 thousand (US$ 355,554 thousand in 2016) incurred by distribution companies.
Cost of Sales. Cost of Sales shall include only those costs and expenses incurred by the Company that (a) would properly be classified as "Cost of Sales" in the Company's consolidated statement of operations and (b) are directly associated or identifiable with New Business Line Revenues. If only a portion of a cost or expense that would otherwise be included in Cost of Sales is directly associated or identifiable with New Business Line Revenues, the Company shall include in the calculation of Net Earnings only that portion of such cost or expense that is directly associated or identifiable with New Business Line Revenues.
Cost of Sales. Represents adjustments comprised of the following: (in millions) Nine Months Ended September 30, 2019 Year Ended December 31, 2018 Depreciation of acquired property, net (i) $ 10.2 $ 11.5 Elimination of cost of sales (ii) 3.6 4.9
i. Represents net impact of removal of historical depreciation expense and increased depreciation expense for the fair value of property, plant, and equipment assets recognized as part of acquisition accounting. Property, plant, and equipment assets are depreciated over their estimated remaining useful lives, determined in accordance with PolyOne's policy.
ii. Represents elimination of cost of goods sold relating to transactions between PolyOne and Clariant Masterbatch that would be considered intercompany transactions and will be eliminated in the consolidated financial statements of the combined company following the Clariant Acquisition
